Are you Dr. Putcha?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 23 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
300 Pasteur Dr
L235
Stanford, CA 94305Phone+1 650-862-6142- Is this information wrong?
Summary
- Dr. Girish Putcha, MD is a pathologist in Stanford, California. He is currently licensed to practice medicine in California, Missouri, and South Carolina.
Education & Training
- Stanford Health Care-Sponsored Stanford UniversityResidency, Pathology-Anatomic and Clinical, 2003 - 2007
- Washington University in St. Louis School of MedicineClass of 2003
Certifications & Licensure
- CA State Medical License 2004 - 2024
- MO State Medical License 2012 - 2022
- SC State Medical License 2011 - 2017
Clinical Trials
- AI-EMERGE: Development and Validation of a Multi-analyte, Blood-based Colorectal Cancer Screening Test Start of enrollment: 2018 Jan 12
Publications & Presentations
PubMed
- Differential impact of test performance characteristics on burden-to-benefit tradeoffs for blood-based colorectal cancer screening: A microsimulation analysis.Andrew Piscitello, Lauren N Carroll, Signe Fransen, Ben Wilson, Tarun Chandra, Reinier Meester, Girish Putcha> ;Journal of Medical Screening. 2023 Dec 1
- 2 citationsBLOODPAC: Collaborating to chart a path towards blood-based screening for early cancer detection.Christina A Clarke, Kathryn Lang, Girish Putcha, Jonathan P Beer, Maude Champagne, Andrea Ferris, James H Godsey, Robert L Grossman, Jody M Hoyos, Donald J Johann, Nan...> ;Clinical and Translational Science. 2023 Jan 1
- 8 citationsMulticancer Screening: One Size Does Not Fit AllGirish Putcha, Alberto Gutierrez, Steven J. Skates> ;JCO Precision Oncology. 2021 Apr 1
- Join now to see all
Press Mentions
- Research Shows the Clinical Benefits of Detecting Adenomas in Multi-Cancer Early Detection Tests That Screen for Colorectal CancerJune 7th, 2022
- Freenome Shows Continued Leadership in Colorectal Cancer ResearchOctober 25th, 2021
- With Illumina Acquisition Pending, GRAIL Presents Multi-Cancer Detection TestJune 7th, 2021
- Join now to see all